Alkermes
ALKS48.3404.28% ( -2.160 )
Alkermes (ALKS)
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs...
- Open
- 50.500
- High
- 50.715
- Low
- 47.660
- Prev. Close
- 50.500
- Volume
- 4.15M
- Turnover
- 201.48M
- Avg Price
- 48.553
- Bid/Ask Ratio
- --
- Amplitude
- 6.05%
- 52wk High
- 55.670
- Volume Ratio
- 2.89
- Turnover Ratio
- 2.69%
Alkermes Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$56.0015.85%
Forecast & RatingBuy
18analysts
- Strong buy61.11%
- Buy16.67%
- Hold16.67%
- Sell0.00%
- Strong sell5.56%
News
- Simplywall · 12 hours ago
Alkermes (ALKS) Stock Revenue Jumps While Margins Lose Steam
- benzinga_article · 1 day ago, 08:20 AM
Alkermes shares are trading lower. The company reported Q2 financial results.
- Quartr · 2 days ago, 06:47 AM
ALKS: Q2 2026 revenue and profitability surged following the Avadel acquisition and product growth
- TradingView · 2 days ago, 06:13 AM
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M
- Market Beat · Jul 24 at 05:10 AM
Alkermes plc $ALKS Shares Bought by Knott David M Jr
- PUBT · Jul 14 at 03:00 PM
Alkermes schedules second-quarter results call and webcast
